

### AMENDMENTS TO THE CLAIMS

Please cancel claims 56-78.

Please add new claims 79-99 as follows:

1-78. **(Canceled)**

79. **(New)** An isolated human monoclonal antibody, or antigen binding portion thereof, that binds to human dendritic cells and comprises (i) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising amino acid residues 31-35 of SEQ ID NO:4, amino acid residues 50-66 of SEQ ID NO:4, and amino acid residues 99-105 of SEQ ID NO:4, respectively; and (ii) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising amino acid residues 24-34 of SEQ ID NO:2, amino acid residues 50-56 of SEQ ID NO:2, and amino acid residues 89-97 of SEQ ID NO:2, respectively.

80. **(New)** An isolated human monoclonal antibody, or antigen binding portion thereof, that binds to human dendritic cells and comprises the human heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4 and the human light chain variable region comprising the amino acid sequence of SEQ ID NO:2.

81. **(New)** An isolated human monoclonal antibody, or antigen binding portion thereof, that binds to human dendritic cells comprising (a) a heavy chain variable region which is the product of a human germline  $V_H$  5-51 gene and (b) a light chain variable region which is the product of a human germline  $V_K$  L15 gene.

82. **(New)** The human antibody, or portion thereof, of claim 79 or claim 81, which is internalized following binding to the cells.

83. **(New)** The human antibody, or portion thereof, of claim 79 or claim 81, which specifically binds to human dendritic cells with an affinity of at least about  $10^8 M^{-1}$ .

84. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which activates human dendritic cells.

85. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which when linked to an antigen, enhances presentation of the antigen by human dendritic cells following binding to the cells in that the targeted antigen is processed and presented more efficiently compared to the same antigen when not linked to the antibody.

86. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which induces cytokine release by human dendritic cells.

87. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which binds to the human macrophage mannose receptor comprising the amino acid sequence shown in SEQ ID NO:7.

88. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which dissociates from dendritic cells with a rate constant  $K_{(dis)}$  of about  $10^{-3} \text{ S}^{-1}$  or less.

89. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which comprises an IgG1 heavy chain.

90. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which comprises a kappa light chain.

91. (New) The human antibody, or portion thereof, of claim 79 or claim 81, which is a single chain antibody or an Fab' fragment.

92. (New) A method of inducing or enhancing an immune response against an antigen in a subject comprising administering to the subject the human antibody, or portion thereof, of claim 79 or claim 81.

93. (New) A method of inducing cytokine release by human dendritic cells in a subject comprising administering to the subject the human antibody, or portion thereof, of claim 79 or claim 81.